Volume 22, Number 11—November 2016
Research
Immune Responses to Invasive Group B Streptococcal Disease in Adults
Table
CPS-specific IgG responses for 87 nonpregnant adults with invasive GBS infection*
GBS type | CPS-specific IgG, GMC (range) [95% CI], μg/mL |
||||
---|---|---|---|---|---|
No. patients† | Acute-phase sample | Convalescent-phase sample | p value‡ | ||
Ia | 22 | 26.0 (0.39–609.1) [9.5–71.0] | 137.6 (0.35–7,792.2) [50.4–375.6] | <0.001 | |
Ib | 13 | 9.3 (0.08–680.9) [1.6–55.6] | 25.2 (0.08–650.5) [4.6–139.5] | 0.035 | |
II | 10 | 11.6 (0.13–1,126.8) [1.2–113.6] | 47.4 (0.61–2,279.9) [6.1–366.1] | 0.032 | |
III | 17 | 1.5 (0.13–153.9) [0.53–4.0] | 4.8 (0.13–584.4) [1.1–20.4] | 0.044 | |
V | 13 | 3.2 (0.24–596.3) [0.51–19.9] | 10.1 (0.43–4,182.0) [1.9–55.0] | 0.003 | |
IV§ | 12 | 409.5 (17.6–4,823.3) [133.3–1,257.5] | 1,060.9 (149.4–9,085.2) [415.7–2,707.6] | 0.022 |
*CPS, capsular polysaccharide; GBS, group B Streptococcus; GMC, geometric mean concentration.
†Excludes 10 patients with infection caused by GBS that did not express capsular polysaccharide, 3 for whom convalescent-phase samples were of insufficient quantity for analysis, and 2 who died before collection of convalescent-phase serum.
‡Paired t-test on log-transformed data.
§Results are expressed in ELISA units/mL.
Page created: October 18, 2016
Page updated: October 18, 2016
Page reviewed: October 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.